Prudential Financial Inc. Raises Stake in Amphastar Pharmaceuticals Inc (NASDAQ:AMPH)

Prudential Financial Inc. boosted its stake in shares of Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) by 8.9% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 61,995 shares of the company’s stock after acquiring an additional 5,085 shares during the period. Prudential Financial Inc. owned about 0.13% of Amphastar Pharmaceuticals worth $1,234,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the business. First Quadrant L P CA purchased a new stake in shares of Amphastar Pharmaceuticals in the fourth quarter valued at about $67,000. LS Investment Advisors LLC raised its holdings in Amphastar Pharmaceuticals by 217.9% during the fourth quarter. LS Investment Advisors LLC now owns 3,522 shares of the company’s stock worth $70,000 after purchasing an additional 2,414 shares in the last quarter. Quantamental Technologies LLC acquired a new stake in Amphastar Pharmaceuticals during the fourth quarter worth approximately $71,000. Meeder Asset Management Inc. acquired a new stake in Amphastar Pharmaceuticals during the fourth quarter worth approximately $92,000. Finally, SG Americas Securities LLC acquired a new stake in Amphastar Pharmaceuticals during the fourth quarter worth approximately $161,000. Institutional investors own 47.51% of the company’s stock.

In other Amphastar Pharmaceuticals news, insider Jason B. Shandell sold 15,497 shares of the business’s stock in a transaction on Wednesday, January 23rd. The shares were sold at an average price of $22.39, for a total transaction of $346,977.83. Following the sale, the insider now directly owns 168,518 shares in the company, valued at approximately $3,773,118.02. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Yakob Liawatidewi sold 7,000 shares of Amphastar Pharmaceuticals stock in a transaction on Wednesday, January 23rd. The stock was sold at an average price of $22.52, for a total value of $157,640.00. Following the transaction, the senior vice president now directly owns 40,463 shares of the company’s stock, valued at approximately $911,226.76. The disclosure for this sale can be found here. Over the last quarter, insiders sold 116,305 shares of company stock worth $2,632,315. 31.50% of the stock is currently owned by insiders.

A number of research firms have weighed in on AMPH. BidaskClub cut shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, April 10th. TheStreet cut shares of Amphastar Pharmaceuticals from a “b-” rating to a “c+” rating in a report on Monday, March 18th. Needham & Company LLC cut shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating and set a $22.20 price objective on the stock. in a report on Wednesday, March 13th. Piper Jaffray Companies cut shares of Amphastar Pharmaceuticals from an “overweight” rating to a “neutral” rating and cut their price objective for the stock from $24.00 to $23.00 in a report on Wednesday, March 13th. Finally, Zacks Investment Research upgraded shares of Amphastar Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, March 5th. Four equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $23.73.

Shares of AMPH traded up $0.08 during mid-day trading on Monday, reaching $20.80. 66,916 shares of the company’s stock were exchanged, compared to its average volume of 193,869. The company has a current ratio of 2.06, a quick ratio of 1.41 and a debt-to-equity ratio of 0.09. The firm has a market cap of $969.49 million, a PE ratio of 99.05, a price-to-earnings-growth ratio of 2.40 and a beta of 1.37. Amphastar Pharmaceuticals Inc has a 52-week low of $14.40 and a 52-week high of $25.43.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its earnings results on Tuesday, March 12th. The company reported $0.13 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.11 by $0.02. Amphastar Pharmaceuticals had a negative net margin of 1.96% and a positive return on equity of 3.17%. The business had revenue of $89.69 million for the quarter, compared to analyst estimates of $75.46 million. As a group, equities research analysts forecast that Amphastar Pharmaceuticals Inc will post 0.35 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was first posted by Baseball Daily News and is the property of of Baseball Daily News. If you are accessing this report on another publication, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this report can be read at https://www.baseballdailydigest.com/news/2019/04/15/amphastar-pharmaceuticals-inc-amph-holdings-boosted-by-prudential-financial-inc.html.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients products.

Recommended Story: What is an Initial Public Offering (IPO)?

Institutional Ownership by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.